# Immunovaccine (IMV)

Source: https://onco.cc/companies/immunovaccine/  
OnCo record `immunovaccine` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immunovaccine (IMV) is a Canadian biotechnology company founded in 2000 in Halifax, Nova Scotia, whose survivin-targeted immunotherapy DPX-Survivac is tested with pembrolizumab and low-dose cyclophosphamide in two OnCo trials, in relapsed diffuse large B-cell lymphoma and in selected solid tumours.

## Summary

Immunovaccine is a company based in Halifax, Canada, founded in 2000 (Wikidata Q30282846, which also gives its website; a second Wikidata item, Q140169711, places Immunovaccine Technologies Inc. in Dartmouth). ClinicalTrials.gov registers it as ImmunoVaccine Technologies, Inc. (IMV Inc.), an industry sponsor, with Merck Sharp & Dohme as collaborator. It leads two phase 2 trials recorded in OnCo: NCT04920617 (VITALIZE, DPX-Survivac and pembrolizumab with and without intermittent low-dose cyclophosphamide in relapsed or refractory DLBCL) and NCT03836352 (the same combination in selected advanced and recurrent solid tumours, recorded under ovarian, hepatocellular, non-small-cell and small-cell lung cancer). DPX-Survivac is its own product, the basis for the biotech type.

## Fields

- Kind: Company
- Last checked: 2026-09-22
- Also known as: ImmunoVaccine Technologies, Inc.; ImmunoVaccine Technologies; IMV Inc.; IMV Inc; Immunovaccine Technologies Inc.
- Tags: ctgov-sponsor; wave5-sponsor
- HQ: Halifax, Nova Scotia
- Type: biotech
- Website: http://www.imvaccine.com/

## Sources

- Official website: http://www.imvaccine.com/
- Wikidata Q30282846: https://www.wikidata.org/wiki/Q30282846
- ClinicalTrials.gov: trials led by ImmunoVaccine Technologies, Inc.: https://clinicaltrials.gov/search?lead=ImmunoVaccine%20Technologies%2C%20Inc.

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp](https://onco.cc/trials/nct04920617/), [Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur](https://onco.cc/trials/nct03836352/)

---
JSON: https://onco.cc/api/v1/entities/immunovaccine.json